Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Brighton Jones LLC

Brighton Jones LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.9% during the third quarter, HoldingsChannel reports. The institutional investor owned 5,400 shares of the biopharmaceutical company’s stock after buying an additional 1,075 shares during the quarter. Brighton Jones LLC’s holdings in Regeneron Pharmaceuticals were worth $4,094,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $5,682,636,000. Legal & General Group Plc acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $473,872,000. Bank of New York Mellon Corp bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $472,950,000. Deutsche Bank AG acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $323,249,000. Finally, Man Group plc bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth $272,460,000. 83.31% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the sale, the executive vice president owned 13,134 shares of the company’s stock, valued at approximately $11,163,900. This represents a 8.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 7,439 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total transaction of $7,219,251.94. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,652,693.38. This trade represents a 81.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 27,028 shares of company stock valued at $25,025,950 over the last quarter. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $904.35 on Monday. The company has a market capitalization of $93.56 billion, a P/E ratio of 19.97, a price-to-earnings-growth ratio of 1.20 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 52-week low of $591.52 and a 52-week high of $991.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.35. The company’s 50 day moving average price is $804.38 and its 200-day moving average price is $742.81.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same period in the prior year, the firm posted $11.83 EPS. The company’s quarterly revenue was up 36.3% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be issued a $0.94 dividend. The ex-dividend date is Friday, November 20th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is presently 8.30%.

Analyst Ratings Changes

A number of equities analysts have issued reports on REGN shares. Sanford C. Bernstein upped their target price on Regeneron Pharmaceuticals from $756.00 to $812.00 and gave the stock a “market perform” rating in a report on Monday, November 2nd. TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a “buy” rating in a report on Wednesday, October 21st. BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Leerink Partners upped their price target on shares of Regeneron Pharmaceuticals from $835.00 to $997.00 and gave the company a “market perform” rating in a research report on Monday, November 2nd. Finally, Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the company an “equal weight” rating in a research note on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $898.97.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.